Strategic Intelligence Report
Generated July 29, 2026
Neurotechnology
Precision Neuroscience
Strategic importance is our editorial rating of how central this entity is to the technology landscape we track; confidence reflects how well-sourced and current the underlying evidence is.
1
Chokepoint Score
1 other entity structurally depend on this one
Headquarters
New York, New York, USA
Website
Employees
119 (2026-05-31)
Founded
2021
Listing
private
Overview
Developer of the Layer 7 Cortical Interface, a thin-film, minimally invasive brain-computer interface that received FDA 510(k) clearance for intraoperative use of up to 30 days, a major extension from prior hours-long limits. Precision Neuroscience has raised roughly $183 million in total funding, partnered with UChicago Medicine researchers in April 2026 to advance BCI research, and is frequently cited as a contender to reach commercialization milestones ahead of Neuralink and Synchron given its less invasive surgical approach.
Dependency Map
One hop in each direction — see Strategic Connections below for the full, sourced breakdown of every relationship.
Strategic Connections
Development
- Brain-Computer Interfaces: Precision Neuroscience develops the Layer 7 Cortical Interface, a thin-film minimally invasive brain-computer interface.
Competition / Other
- Neuralink: Precision Neuroscience competes with Neuralink, offering a less invasive cortical-surface electrode approach versus Neuralink's penetrating implant.
- Synchron: Precision Neuroscience competes with Synchron in the race toward BCI regulatory and commercial milestones.
- Paradromics: Precision Neuroscience competes with Paradromics, which completed the first-in-human implant of its wireless Connexus BCI in 2026, both pursuing speech-restoration applications.
Strategic Risks
- Commercialization path from cleared device to durable revenue still unproven
- Competes against far better-funded Neuralink
Future Outlook
- Positioned as a potential first-mover to commercialization given its less invasive, already-cleared device
- Targeting a share of an estimated $2 billion near-term BCI market
Sources
- Fierce Biotech / MedTech Dive (Apr 2025) — FDA clears Precision Neuroscience's minimally invasive brain-computer interface implant
- We Will Cure / industry research (Apr 2026) — Precision Neuroscience partners with UChicago Medicine on BCI research
Generated by InsightNodes — Technology Intelligence Platform. This report reflects sourced, evidence-backed information as of the dates cited above and is not investment advice.
Viewing the Full Analyst Report — switch to the Executive Summary.